MP45-20 RASAL2, A NOVEL RAS GTPASE ACTIVATING PROTEIN, INHIBITS STEMNESS AND EPITHELIAL-MESENCHYMAL TRANSITION VIA MAPK/SOX2 PATHWAY IN BLADDER CANCER
Ke Hui,Kaijie Wu,Jinhai Fan,Dalin He
DOI: https://doi.org/10.1016/j.juro.2016.02.297
IF: 7.6
2016-01-01
The Journal of Urology
Abstract:You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I1 Apr 2016MP45-20 RASAL2, A NOVEL RAS GTPASE ACTIVATING PROTEIN, INHIBITS STEMNESS AND EPITHELIAL-MESENCHYMAL TRANSITION VIA MAPK/SOX2 PATHWAY IN BLADDER CANCER Ke Hui, Kaijie Wu, Jinhai Fan, and Dalin He Ke HuiKe Hui More articles by this author , Kaijie WuKaijie Wu More articles by this author , Jinhai FanJinhai Fan More articles by this author , and Dalin HeDalin He More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.297AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Patients with bladder cancer (BCa) have high incidence of relapse and metastasis. Unfortunately, the molecular mechanism of these processes remains poorly understood. In our study, we demonstrate RASAL2, a novel RAS GTPase activating protein (RASGAP), is a suppressor in BCa, which modulates cancer stemness and epithelial-mesenchymal transition (EMT) contributing to relapse and metastasis of BCa. METHODS Bladder cancer tissues consisting of normal (N=10), low grade (N=84) and high grade (N=48) were immunohistochemically stained for RASAL2. In vitro, RASAL2 gain-function in T24 and 253J-BV cells or loss-function in 5637 and 253J cells were measured for migration, invasion, stemness, colony formation by Boyden chamber assay, tumorsphere assay, colony formation assay, immuoflurescence staining, qRT-PCR and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tumorgenicity, and the expression of RASAL2, CD44 and E-cadherin was detected by immuohistochemical (IHC) staining. RESULTS RASAL2 was down-regulated in BCa tissues, and inversely correlated with BCa stages and grades. Overexpressed RASAL2 could suppress stemness, EMT and colony formation in T24 or 253J-BV cells, while RASAL2 knockdown (KD) enhanced stemness, EMT and colony formation in 5637 or 253J cells in vitro. RASAL2 KD could also enhance tumorigenicity in xenografts. Mechanistically, RASAL2 KD could enhance the phosphorylation of ERK, and increase the expression of SOX2. Using a MEK1/2 specific inhibitor U0126 or SOX2 KD could rescue stemness and EMT in RASAL2 KD cell lines. CONCLUSIONS RASAL2 is down-regulated in BCa tissues, which could inhibit stemness and EMT via MAPK/SOX2 signaling pathway. Overall, RASAL2 can be a potential target to prevent BCa relapse and metastasis. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e616 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Ke Hui More articles by this author Kaijie Wu More articles by this author Jinhai Fan More articles by this author Dalin He More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...